In vitro evaluation of temozolomide combined with X-irradiation

Article Properties
Cite
Wedge, Stephen R., et al. “In Vitro Evaluation of Temozolomide Combined With X-Irradiation”. Anti-Cancer Drugs, vol. 8, no. 1, 1997, pp. 92-97, https://doi.org/10.1097/00001813-199701000-00013.
Wedge, S. R., Porteous, J. K., Glaser, M. G., Marcus, K., & Newlands, E. S. (1997). In vitro evaluation of temozolomide combined with X-irradiation. Anti-Cancer Drugs, 8(1), 92-97. https://doi.org/10.1097/00001813-199701000-00013
Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anti-Cancer Drugs. 1997;8(1):92-7.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
Citations
Title Journal Journal Categories Citations Publication Date
ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines Oncotarget 1 2024
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma Nature Biomedical Engineering
  • Medicine: Medicine (General): Medical technology
  • Science: Biology (General)
  • Science: Chemistry: Organic chemistry: Biochemistry
 12 2021
Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies

 Clinical Neuropharmacology
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
 2021
Malignant optic nerve glioma in a young woman with 7 year follow up without recurrence American Journal of Ophthalmology Case Reports 1 2020
Pseudoprogression as an adverse event of glioblastoma therapy

 Cancer Medicine
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 37 2017
Citations Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens65
Medicine: Medicine (General)58
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system22
Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine18
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry17
Medicine: Therapeutics. Pharmacology11
Medicine: Public aspects of medicine: Toxicology. Poisons7
Science: Biology (General)6
Medicine: Surgery6
Science: Chemistry: Organic chemistry: Biochemistry5
Technology: Electrical engineering. Electronics. Nuclear engineering: Nuclear engineering. Atomic power3
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs3
Medicine: Pediatrics2
Medicine: Internal medicine1
Science: Chemistry: Organic chemistry1
Science: Chemistry: General. Including alchemy1
Science: Chemistry1
Medicine: Pathology1
Science: Physics1
Science: Biology (General): Cytology1
Medicine: Dermatology1
Science: Biology (General): Genetics1
Agriculture: Plant culture1
Agriculture: Animal culture1
Agriculture: Animal culture: Veterinary medicine1
Technology: Chemical technology: Biotechnology1
Medicine: Medicine (General): Medical technology1
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 65 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Investigational approaches to the treatment of brain tumors in children and was published in 1999. The most recent citation comes from a 2024 study titled ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. This article reached its peak citation in 2009, with 13 citations. It has been cited in 62 different journals, 8% of which are open access. Among related journals, the International Journal of Radiation Oncology*Biology*Physics cited this research the most, with 8 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year